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a  b  s  t  r  a  c  t
Clostridium difﬁcile is a leading cause of diarrhea in hospitalized patients worldwide. While
metronidazole and vancomycin are the most prescribed antibiotics for the treatment of this
infection, teicoplanin, tigecycline and nitazoxanide are alternatives drugs. Knowledge on
the  antibiotic susceptibility proﬁles is a basic step to differentiate recurrence from treat-
ment  failure due to antimicrobial resistance. Because C. difﬁcile antimicrobial susceptibility
is  largely unknown in Brazil, we aimed to determine the proﬁle of C. difﬁcile strains cultivated
from stool samples of inpatients with diarrhea and a positive toxin A/B test using both agar
dilution and disk diffusion methods. All 50 strains tested were sensitive to metronidazole
according to CLSI and EUCAST breakpoints with an MIC90 value of 2 g/mL. Nitazoxanide
and  tigecycline were highly active in vitro against these strains with an MIC90 value of
0.125  g/mL for both antimicrobials. The MIC90 were 4 g/mL and 2 g/mL for vancomycin
and teicoplanin, respectively. A resistance rate of 8% was observed for moxiﬂoxacin. Disk
diffusion can be used as an alternative to screen for moxiﬂoxacin resistance, nitazoxanide,
tigecycline and metronidazole susceptibility, but it cannot be used for testing glycopep-
tides. Our results suggest that C. difﬁcile strains from São Paulo city, Brazil, are susceptible
to  metronidazole and have low MIC90 values for most of the current therapeutic optionsavailable in Brazil.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
and cytotoxin B, that can cause diarrhea, pseudomembranous
Introduction
Clostridium difﬁcile is a spore-forming Gram-positive bacillus.
This microorganism produces two major toxins, enterotoxin A
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colitis, colon dilation, sepsis, and even death.1
The incidence and severity of C. difﬁcile infections (CDI) is
growing in many  countries due in part to the dissemination of
lsevier Editora Ltda. This is an open access article under the CC
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 hyper virulent strain known as North America Pulse type 1
NAP1) or ribotype 027.2
Until the 1980s, there was little interest in research-
ng new antibiotics for the treatment of CDI because most
atients responded well to treatment with metronidazole or
ral vancomycin. More  recently, infection recurrence and the
imitations of the available therapeutic options have become
learer.3 There are still doubts about the accuracy and corre-
ation of different methods used to evaluate in vitro antibiotic
ensitivity as well as the sensitivity of C. difﬁcile strains to the
ecommended treatment regimens.
This study assessed the susceptibility proﬁles of a collec-
ion of C. difﬁcile strains cultivated from stools of inpatients
ith diarrhea in six tertiary hospitals in São Paulo, Brazil. We
lso aimed to evaluate if disk diffusion method could be an
lternative for susceptibility testing of the main drugs used
n the treatment of CDIs. It was not a purpose of the study to
valuate the epidemiological data of the patients.
aterials  and  methods
lostridium  difﬁcile  strains
onsecutive clinical strains of Clostridium difﬁcile (n = 50) were
ultivated from stool samples of inpatients with diarrhea in
ix tertiary hospitals in São Paulo from March to December
013 (one sample per patient). Stool samples were randomly
elected for culture based on their positivity when tested
ith the ProScpectTM C. difﬁcile Toxin A/B Microplate Assay
Thermo Scientiﬁc). Stool cultures for C. difﬁcile were carried
ut as previously described, with modiﬁcations.4 In sum-
ary, approximately 0.5 g of feces were mixed with 0.5 mL
5% ethanol, vortexed and incubated at room temperature
20–25 ◦C) for 1 h. The suspension was vortxed again and
wo drops were plated on Brucella agar supplemented with
% horse blood and 0.2% sodium taurocholate. Plates were
ncubated in a 2.5 L anaerobic jar containg the Atmosphere
eneration System AnaeroGen (Oxoid-Thermo Scientiﬁc) for
2 h at 36 ◦C. Identiﬁcation to the species level was achieved by
ALDI-ToF MS using the MALDI Biotyper LT System (Bruker).
The strains were stored in 10% skim milk at −70 ◦C and
ubcultured on Brucella agar with 5% horse blood twice before
tilization in susceptibility tests.
ntimicrobial  susceptibility  testing
he antimicrobials tested in this study were: metronida-
ole (Sigma-Aldrich), moxiﬂoxacin (Sigma-Aldrich), nitazox-
nide (Farmoquímica), teicoplanin (Sigma-Aldrich), tigecy-
line (Pﬁzer), and vancomycin (Sigma-Aldrich).
Disk diffusion was performed as described by Erikstrup
t al.5 Cultured strains were suspended in thioglycollate broth
o a density of 1.0 McFarland (≈3.0 × 108 CFU/mL) with the
id of DensiCheck® (bioMérieux). The suspension was then
eeded onto Brucella Blood Agar supplemented with 10% sterile
eﬁbrinated lysed horse blood, hemin (5 g/mL) and vitamin
 (1 g/mL). To optimize the growth of C. difﬁcile,  plates were
re-reduced for 24 h in an anaerobic atmosphere generated
y the AnaeroGen system (Oxoid-Thermo Scientiﬁc) before6;2 0(5):476–481 477
use. For inoculum preparation, inoculation and incubation the
15-15-15 rule was followed.5
After 24 h of incubation at 36 ◦C in anaerobic atmosphere,
generated with the aid of the AnaeroGen Atmosphere Gen-
eration Systems (Oxoid-Thermo Scientiﬁc), inhibition zone
diameters were measured under reﬂected light considering
100% inhibition. Duplicate tests were performed for each
strain on two separate days. The inhibition zone diameters
were correlated with the minimum inhibitory concentrations
(MICs) obtained by agar dilution for each strain and drug com-
bination.
For nitazoxanide and metronidazole 6-mm paper disks
were prepared by adding 10 L of a 0.5 mg/mL  solution
in dimethyl sulfoxide (Sigma), while for vancomycin and
teicoplanin 6-mm paper disks with a potency of 5 g were pre-
pared by adding 10 L of a 0.5 mg/mL  solution in reagent grade
water. A 30 g teicoplanin disk (Oxoid-Thermo Scientiﬁc) was
also tested. For tigecycline and moxiﬂoxacin, we  used com-
mercially available disks (Oxoid-Thermo Scientiﬁc) containing
15 and 5 g, respectively. There are currently no interpretative
criteria for disk diffusion when testing C. difﬁcile.
For agar dilution bacterial strains were tested according
to the Clinical and Laboratory Standards Institute (CLSI)6
and the European Committee on Antimicrobial Susceptibil-
ity Testing (EUCAST)7 guidelines. Bacterial suspensions were
prepared in thioglycollate broth to 0.5 McFarland turbidity
(≈1.5 × 108 CFU/mL) before 1 L of each suspension was trans-
ferred to the agar plates with the aid of a Steers replicator.
Plates containing antibiotic were stamped starting from the
lowest concentration. The MIC was deﬁned as the lowest
antibiotic concentration inhibiting visible growth after 48 h of
incubation at 37 ◦C in anaerobiosis. Tests were performed in
duplicates.
The CLSI breakpoints for MICs were used for metronida-
zole and moxiﬂoxacin,8 while EUCAST criteria were used
for metronidazole and vancomycin.7 The interpretative crite-
ria are summarized in Table 2. There are currently no
interpretative criteria for tigecycline, teicoplanin, and nita-
zoxanide; consequently, only MIC50 and MIC90 values were
calculated. For teicoplanin and nitazoxanide, the ECOFFinder
spreadsheet9 was used to estimate epidemiological cut-off
values (ECOFFs). C. difﬁcile ATCC 700057 strain was  used for
quality control and tested simultaneously with each batch of
antimicrobial susceptibility tests.
Statistical  analysis
For metronidazole, moxiﬂoxacin, and vancomycin categorical
agreement between agar dilution and tentative interpreta-
tive criteria for disk diffusion was evaluated using CLSI and
EUCAST breakpoints for agar dilution. The errors were classi-
ﬁed as previously described.10
ResultsFrom March 1st to December 31st 2013 there were 1884
patients for which the detection of C. difﬁcile toxins A and B by
ELISA was ordered by the attending physicians. A total of 239
(12.7%) patients had a positive test. The mean age of patients
478  b r a z j i n f e c t d i s . 2 0
Table 1 – Minimal inhibitory concentrations and
inhibition zone diameters obtained for C. difﬁcile ATCC
700057 by the agar dilution and disk diffusion methods.
Antimicrobial Agar dilution (g/mL) Disk diffusion (mm)
Metronidazole 0.25–0.5 38–42
Moxiﬂoxacin 0.5–4 22–25
Nitazoxanide 0.06–0.125 26–30
Teicoplanin 0.25–2 15–20a
24–28b
Tigecycline 0.06–0.125 35–40
Vancomycin 0.25–2 21–25
13a 5 g teicoplanin disk.
b 30 g teicoplanin disk.
with a positive test result was 61.3 years and most (61.1%) were
female. A total of 50 fecal samples were ramdomly  selected
and cultured for isolation of C. difﬁcile. The recovery rate was
100%. These isolates were conﬁrmed to be C. difﬁcile by mass
spectrometry and were used for susceptibility tests.
All the MIC  results for the quality control strain C. difﬁcile
ATCC 700057 were inside the expected range recommended by
the CLSI (Table 1). For teicoplanin, for which there is no CLSI
or EUCAST expected range for this strain, the MIC range was
0.25–2 g/mL and the inhibition zone diameter ranged from
15 to 20 mm and 24 to 28 mm for the 5 g and 30 g disks,
respectively (Table 1).
All tested strains were susceptible to metronidazole both by
CLSI and EUCAST criteria. The MIC50 and MIC90 values are dis-
played in Table 2. Using 30 mm as the susceptibility breakpoint
for disk diffusion there would be 100% category agreement
between agar dilution and disk diffusion methods (Fig. 1A).
There are currently no CLSI breakpoints for glycopeptides
when testing C. difﬁcile.  Twenty-one strains (42%) had an MIC
≤2 g/mL for vancomycin and were classiﬁed as susceptible
using the EUCAST breakpoint for C. difﬁcile.  MIC50 and MIC90
values are displayed in Table 2.
Using the 2 g/mL EUCAST susceptibility breakpoint for
vancomycin none of the values obtained for inhibition zone
diameter would result in a major error rate under 1.5% (Fig. 1B).
The same was observed for teicoplanin (Fig. 1C and D), if we
use the same EUCAST susceptibility breakpoint available for
vancomycin, both with the he 5 g or the 30 g disks.
For nitazoxanide, the interpretation criteria for DD and MIC
have not been deﬁned by CLSI or EUCAST. The MIC50 and MIC90
values are displayed in Table 2. All strains with an inhibition
Table 2 – Susceptibility proﬁle of 50 Clostridium difﬁcile isolates 
Antimicrobial MIC50
(g/mL)
MIC90
(g/mL)
Susceptible (%) Res
CLSI EUCAST CLSI 
Metronidazole 1 2 100 100 0 
Moxiﬂoxacin 4 4 6 – 8 
Nitazoxanide 0.06 0.12 – – – 
Teicoplanin 2 2 – – – 
Tigecycline 0.12 0.12 – – – 
Vancomycin 4 4 – 42 –  1 6;2  0(5):476–481
zone diameter ≥24 mm had an MIC  value ≤0.25 g/mL, the
calculated ECOFF value (Fig. 1E).
There are currently no tigecycline susceptibility break-
points according to CLSI or EUCAST. The MIC50 and MIC90 are
displayed in Table 2. The calculated ECOFF was 0.25 g/mL. All
isolates, except one, had an inhibition zone diameter ≥30 mm
and an MIC higher than 0.25 g/mL (Fig. 1F).
For moxiﬂoxacin, both the MIC50 and MIC90 were 4 g/mL
(Table 2). Four (8%) strains had high MIC values of 32 g/mL
(Fig. 1G). Applying the CLSI susceptibility breakpoint of
2 g/mL for moxiﬂoxacin, only 6% of the strains would be con-
sidered susceptible. Using this MIC breakpoint, none of the
values obtained for inhibition zone diameter would result in
a very major error rate under 1.5%.
Discussion
We evaluated the antimicrobial susceptibility proﬁle of a col-
lection of 50 C. difﬁcile strains using both agar dilution and disk
diffusion.
All strains were susceptible to metronidazole, and the
highest MIC value was 2 g/mL, two dilutions bellow the sus-
ceptibility breakpoint of 8 g/mL recommended by the CLSI.
These ﬁndings agree with a recent publication that evaluated
a large collection of strains from Europe and found the same
MIC90 values.11
Although we  did not detect resistant strains, metronidazole
resistance in C. difﬁcile has been reported very rarely. Freeman
et al.11 found only one isolate with an MIC  value ≥8 g/mL
among 916 tested by agar dilution. Concerning the metronida-
zole disk diffusion method5,5,12 we found that an inhibition
zone diameter ≥30 mm for a metronidazole disk containing
5 g can be indicative of susceptibility, while Erikstrup and
colleagues5 recommend using 23 mm as the breakpoint. This
difference between breakpoints is most probably due to the
number of strains tested in this work, but all strains classi-
ﬁed as susceptible by the 30 mm breakpoint would also be
classiﬁed as susceptible with the 23 mm breakpoint.
Oral metronidazole has been recommended as the treat-
ment of choice for mild disease while oral vancomycin is
usually recommended for the treatment of severe infections
and recurrences. In this study the MIC90 for vancomycin
was 4 g/mL, which is one dilution above the value found
by Freeman et al.11 Our results may not be comparable to
theirs, because they used the Wilkins-Chalgren agar and we
by agar dilution.
istant (%) Susceptibility
breakpoint (g/mL)
Concentration
range tested
(g/mL)
EUCAST CLSI EUCAST
0 ≤8 ≤2 0.25–32
– ≤2 – 0.25–32
– – – 0.03–4
– – – 0.25–32
– – – 0.03–16
58 – ≤2 0.25–32
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sed Brucella agar. Baines et al.14 demonstrated that MIC val-
es obtained using Brucella agar for agar dilution were lower
han those obtained when using Etest strips. Erikstrup and
olleagues5 used the Etest and not the gold standard agar
ilution. Consequently, this may explain why we  did not
nd good correlation between disk diffusion and agar dilu-
ion methods. Our results contrast to those from Erikstrup
nd colleagues,5 since in this work no inhibition zone size
ould result in a very major error rate below 1.5%. Our results
gree well with previous ﬁndings that supported the witdrawal
f the interpretative criteria for vancomycin disk diffusion,
hen testing Staphylococcus,  from CLSI documents.15 There are
o CLSI interpretative criteria for vancomycin when testingC. difﬁcile,  while EUCAST recommends a susceptibility break-
point of 2 g/mL. Based on this breakpoint, Freeman et al.11
reported a low (0.87%) resistance rate when testing a large
collection of strains. Although the results from this study
are different from those of Freeman et al.,11 our ﬁndings
are supported by the fact that the mean vancomycin MICs
obtained for the quality control strain C. difﬁcile ATCC 700057
was 2 g/mL, which is one dilution below the upper limit.8
Teicoplanin and nitazoxanide are alternative treatments
for CDI3,16 but there are currently no susceptibility breakpoints
deﬁned by EUCAST or CLSI. The MIC90 obtained for teicoplanin
in this study is two dilutions above that obtained by Barbut
et al.17 This difference is probably due to the fact that we
i s . 2 0
r
1
1
1
1
1
15. Swenson JM, Anderson KF, Lonsway DR, et al. Accuracy of480  b r a z j i n f e c t d 
used Brucella agar and they used Wilkins-Chalgren agar. Baines
et al.14 demonstrated that agar dilution with Wilkins-Chalgren
agar generates results one dilution lower than those generated
by Brucella agar.
In this study the MIC90 for nitazoxanide was 0.125 g/mL.
This ﬁnding agrees with a previous study from Freeman et al.18
that tested strains from ribotypes 001, 027 and 106 with
reduced susceptibility to metronidazole. To date there are no
reports on the nitazoxanide disk diffusion method for C. difﬁ-
cile. Although in this work we  did not ﬁnd nitazoxanide isolates
with high MICs, our results indicate that 24 mm could be used
as a screening for isolates with MICs ≤0.125 g/mL.
There are some reports in the literature that describe
tigecycline as an alternative therapeutic option for patients
with refractory CDI.19 In this study we obtained an MIC90 of
0.125 g/mL for this antimicrobial. This value is the same as
obtained by Hecht et al.20 There are currently no EUCAST or
CLSI susceptibility breakpoints for tigecycline when testing
C. difﬁcile,  but EUCAST recommends an ECOFF of 0.25 g/mL.
Using this value as a susceptibility breakpoint, 98% of the
strains would be considered susceptible. There are currently
no reports on disk diffusion for tigecycline when testing C.
difﬁcile. Although in this work we did not ﬁnd isolates with a
high tigecycline MICs, our results indicate that 30 mm could
be used as a screening for isolates with MICs ≤0.5 g/mL.
Resistance to ﬂuoroquinolones has been suggested as
a screening for the presence of the hyper virulent strain
NAP1/BI/027.21,22 CLSI recommends 2 g/mL as the suscepti-
bility breakpoint value, while strains with an MIC of 4 g/mL
should be classiﬁed as intermediate. EUCAST has no suscepti-
bility breakpoint for moxiﬂoxacin when testing C. difﬁcile,  but
recommends an ECOFF value of 4 g/mL.
In this study the MIC90 was 4 g/mL and four strains had
an MIC  ≥32 g/mL. Using CLSI breakpoints 6% of the strains
would be classiﬁed as susceptible, 86% intermediate, and 8%
resistant. This resistance rate is much lower than that found
in Europe (39.9%) by Freeman and colleagues.11 To date there
is no report on the presence of the 027 ribotype emerging in
Brazil and possibly this low resistance rate indicates the pre-
dominance of ribotypes other than 027, but ribotyping was
not performed in this study. If we  had used 13 mm as the
resistance breakpoint, then the four resistant strains would
have been detected. We  found a superposition of intermedi-
ate and susceptible categories by disk diffusion. Consequently,
this method cannot be used to preview susceptibility but can
be used to screen for moxiﬂoxacin resistance.
Conclusions
All strains tested in this study were susceptible to metronida-
zole according to EUCAST and CLSI breakpoints. Nitazoxanide
and tigecycline were higly active, both with an MIC90 of
0.125 g/mL. The MIC90 were 4 g/mL and 2 g/mL for van-
comycin and teicoplanin, respectively.
The disk diffusion method can be used to screen for
metronidazole, tigecycline and nitazoxanide susceptibility,
and moxiﬂoxacin resistance but cannot be used for testing
vancomycin and teicoplanin. 1 6;2  0(5):476–481
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